Comparison of Effects of a Thrombin-Based Hemostatic Agent and Topical Tranexamic Acid on Blood Loss in Patients with Preexisting Thromboembolic Risk Undergoing a Minimally Invasive Total Knee Arthroplasty. A Prospective Randomized Controlled Trial
Table 2
Details of the patients (continuous data are presented as mean (standard deviation)).
TXA ()
Floseal® ()
Placebo ()
p value
Age(yr) (SD; range)
69.35 (7.11; 55-80)
69.71 (6.79; 52-81)
69.71 (5.94; 56-79)
0.967
BMI (kg/m2)
27.66 (4.11; 20.19-37.50)
29.38 (4.73; 22.8-39.2)
28.59 (3.73; 21.3-38.4)
0. 248
Women (%)
28/34 (82.4%)
28/34 (82.4%)
32/35 (91.4%)
0.376
ASA-1
2/34 (5.9%)
1/34 (2.9%)
1/35 (2.9%)
0.750
ASA-2
23/34 (67.6%)
19/34 (55.9%)
23/35 (65.7%)
ASA-3
9/34 (26.5%)
14/34 (41.2%)
11/35 (31.4%)
PT
10.15 (0.38; 9.6-11.6)
10.07 (0.48; 9.3-11.9)
10.09 (0.60; 9.3-12.7)
0.753
APTT
27.92 (2.27; 23-33)
27.17 (2.72; 15.3-31.6)
27.70 (2.55; 22.8-33.7)
0.456
Preoperative-Hb (g/dl)
13.02 (1.18; 10.2-16.3)
13.22 (1.18; 11.4-16.5)
12.87 (0.88; 11.3-14.8)
0.408
Preoperative-Hct (%)
39.11 (3.08; 32.4-46.6)
40.07 (2.99; 35.5-47.0)
39.17 (2.56; 35.1-43.6)
0.310
Platelet count (10000/L)
238.00 (48.75; 119-332)
226.56 (51.68; 120-360)
248.37 (58.18; 127-380)
0.238
TXA: tranexamic acid; SD: standard deviation; BMI: body mass index; ASA: American Soceity of Anesthesiologists; PT: prothrombic time; APTT: activated partial thromboplastin time.
